CPI 1205

Drug Profile

CPI 1205

Alternative Names: CPI1205

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Constellation Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer
  • Phase I B cell lymphoma
  • Preclinical Multiple myeloma

Most Recent Events

  • 12 Dec 2017 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Combination therapy, Hormone refractory) in USA (unspecified route)
  • 03 Dec 2016 Preclinical trials in Multiple myeloma in USA (unspecified route)
  • 01 Mar 2015 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (unspecified route) (NCT02395601)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top